Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | ALPG | P10696 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4673153 | 0.91 | HDAC1 (0.67) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL10092882 | 0.89 | HDAC1 (0.49) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL4676323 | 0.83 | HDAC1 (0.64) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL4676966 | 0.80 | HDAC1 (0.65) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL4785853 | 0.76 | HDAC1 (0.53) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| Zabadinostat SCHEMBL29678731 | 0.74 | HDAC1 (0.77) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| Zabadinostat SCHEMBL4785187 | 0.74 | HDAC1 (0.77) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL4675599 | 0.74 | HDAC1 (0.69) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL4678839 | 0.74 | HDAC1 (0.75) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL4677886 | 0.73 | HDAC1 (0.67) | HDAC1HDAC3HDAC2HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735429-B2 | Benzamide compounds useful as histone deacetylase inhibitors | ASTRAZENECA AB (SE) | 2014-05-27 | — | — | US | disclosed |
| EP-1954690-B1 | BENZAMIDE COMPOUNDS USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2013-05-15 | — | — | EP | disclosed |
| US-20120225907-A1 | BENZAMIDE COMPOUNDS USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2012-09-06 | — | — | US | disclosed |
| US-8207202-B2 | N-(2-aminophenyl)-4-{1-[(5-methoxy-1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin-4-yl}benzamide, for example; use as an antiproliferative agent in the prevention or treatment of tumors or other proliferative conditions, which are sensitive to the inhibition of histone deacetylase | ASTRAZENECA AB (SE) | 2012-06-26 | — | — | US | disclosed |
| US-20080269294-A1 | N-(2-aminophenyl)-4-{1-[(5-methoxy-1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin-4-yl}benzamide, for example; use as an antiproliferative agent in the prevention or treatment of tumors or other proliferative conditions, which are sensitive to the inhibition of histone deacetylase | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| EP-1954690-A1 | BENZAMIDE COMPOUNDS USEFUL AS HISTONE DEACETYLASE INHIBITORS | Astra Zeneca AB (SE) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007045844-A1 | BENZAMIDE COMPOUNDS USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225907-A1 | BENZAMIDE COMPOUNDS USEFUL AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885HDAC3 5/4885HDAC2 4/4885 |
| US-20080269294-A1 | N-(2-aminophenyl)-4-{1-[(5-methoxy-1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin-4-yl}benzamide, for example; use as an antiproliferative agent in the prevention or treatment of tumors or other proliferative conditions, which are sensitive to the inhibition of histone deacetylase | HDAC1, HDAC5, HDAC2 | HDAC1 1/4885HDAC3 5/4885HDAC2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.